Metsera reported encouraging phase I data for its long-acting amylin analogue MET-233i, indicating dose-dependent weight loss efficacy and potential for once-monthly dosing. The therapy exhibited up to 8.4% placebo-adjusted weight loss over five weeks and a pharmacokinetic profile that supports extended dosing intervals. These findings position Metsera's candidate as a competitor to weekly injectable GLP-1 receptor agonists, with plans to explore combination treatments with GLP-1 drugs.